Specific TCR V–J gene segment recombinations leading to the identification pan-V–J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma

References

• Miller TP, Dahlberg S. Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by southwest oncology group. Cancer Treat Res. 1993;66:53–63.
   PubMedGoogle Scholar
• Susanibar-Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617–629.
   PubMed Web of Science ®Google Scholar
• Abdulla M, Alexsson A, Sundstrom C, et al. PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS. Acta Oncol. 2021;60(4):531–538.
   PubMed Web of Science ®Google Scholar
• Garcia-Recio M, Wudhikarn K, Pennisi M, et al. The International Prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2021;27(3):233–240.
   PubMedGoogle Scholar
• Olschewski V, Witte HM, Bernard V, et al. Systemic inflammation and tumour-infiltrating T-cell receptor repertoire diversity are predictive of clinical outcome in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Cancers. 2021;13(4):887.
   PubMed Web of Science ®Google Scholar
• Apollonio B, Ioannou N, Papazoglou D, et al. Understanding the immune-stroma microenvironment in B cell malignancies for effective immunotherapy. Front Oncol. 2021;11:626818.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830.e14.
   PubMed Web of Science ®Google Scholar
• Brown SD, Raeburn LA, Holt RA. Profiling tissue-resident T cell repertoires by RNA sequencing. Genome Med. 2015;7(1):125.
   PubMed Web of Science ®Google Scholar
• Li B, Li T, Wang B, et al. Ultrasensitive detection of TCR hypervariable-region sequences in solid-tissue RNA-seq data. Nat Genet. 2017;49(4):482–483.
   PubMed Web of Science ®Google Scholar
• Gill TR, Samy MD, Butler SN, et al. Detection of productively rearranged TcR-α V–J sequences in TCGA exome files: implications for tumor immunoscoring and recovery of antitumor T-cells. Cancer Inform. 2016;15:23–28.
   PubMed Web of Science ®Google Scholar
• Zaman S, Chobrutskiy BI, Patel JS, et al. Antiviral T cell receptor complementarity determining region-3 sequences are associated with a worse cancer outcome: a pancancer analysis. Viral Immunol. 2020.
   Google Scholar
• Tu YN, Tong WL, Fawcett TJ, et al. Lung tumor exome files with T-cell receptor recombinations: a mouse model of T-cell infiltrates reflecting mutation burdens. Lab Invest. 2017;97(12):1516–1520.
   PubMed Web of Science ®Google Scholar
• Tu YN, Tong WL, Samy MD, et al. Assessing microenvironment immunogenicity using tumor specimen exomes: co-detection of TcR-alpha/beta V(D)J recombinations correlates with PD-1 expression. Int J Cancer. 2017;140(11):2568–2576.
   PubMed Web of Science ®Google Scholar
• Li B, Li T, Pignon JC, et al. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet. 2016;48(7):725–732.
   PubMed Web of Science ®Google Scholar
• Tu YN, Tong WL, Callahan BM, et al. B-cell receptor recombinations in lung adenocarcinoma exome files correlate with a higher overall survival rate. Anticancer Res. 2020;40(4):2043–2051.
   PubMed Web of Science ®Google Scholar
• Tu YN, Tong WL, Yavorski JM, et al. Immunogenomics: a negative prostate cancer outcome associated with TcR-γ/δ recombinations. Cancer Microenviron. 2018;11(1):41–49.
   PubMed Web of Science ®Google Scholar
• Yeagley M, Chobrutskiy BI, Gozlan EC, et al. Electrostatic complementarity of T-Cell Receptor-Alpha CDR3 domains and mutant amino acids is associated with better survival rates for sarcomas. Pediatr Hematol Oncol. 2021;38:1–14.
   PubMed Web of Science ®Google Scholar
• Huda TI, Mihyu M, Gozlan EC, et al. Specific HLA alleles, paired with TCR V- and J-gene segment usage, link to distinct multiple myeloma survival rates. Leuk Lymphoma. 2021;62(7):1711–1715.
   PubMed Web of Science ®Google Scholar
• Gozlan EC, Chobrutskiy BI, Zaman S, et al. Systemic adaptive immune parameters associated with neuroblastoma outcomes: the significance of gamma-delta T cells. J Mol Neurosci. 2021;71(11):2393–2404.
   PubMed Web of Science ®Google Scholar
• Chobrutskiy A, Chobrutskiy BI, Zaman S, et al. Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer. Breast Cancer Res Treat. 2021;185(3):591–600.
   PubMed Web of Science ®Google Scholar
• Hsiang M, Chobrutskiy BI, Diaz M, et al. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates. Transl Oncol. 2021;14(6):101069.
   PubMed Web of Science ®Google Scholar
• Chobrutskiy BI, Chobrutskiy A, Zaman S, et al. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG–PIK3CA interactions and breast cancer. Mol Immunol. 2021;135:247–253.
   PubMed Web of Science ®Google Scholar
• Arturo JF, Chobrutskiy BI, Yeagley M, et al. Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates. Cell Mol Immunol. 2020;17(7):776–778.
   PubMed Web of Science ®Google Scholar
• Chobrutskiy BI, Yeagley M, Diviney A, et al. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates. Immunology. 2020;159(4):373–383.
   PubMed Web of Science ®Google Scholar
• Chobrutskiy BI, Yeagley M, Tipping P, et al. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene. 2020;39(8):1773–1783.
   PubMed Web of Science ®Google Scholar
• Diaz MJ, Chobrutskiy BI, Zaman S, et al. Immunogenomics of colorectal adenocarcinoma: survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. Cancer Treat Res Commun. 2020;24:100196.
   PubMedGoogle Scholar
• Arndt MF, Koohestani DM, Chobrutskiy BI, et al. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. Hum Immunol. 2020;81(12):692–696.
   PubMed Web of Science ®Google Scholar
• Roca AM, Chobrutskiy BI, Callahan BM, et al. T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates. Hum Immunol. 2019;80(4):237–242.
   PubMed Web of Science ®Google Scholar
• Chobrutskiy BI, Zaman S, Diviney A, et al. T-cell receptor-alpha CDR3 domain chemical features correlate with survival rates in bladder cancer. J Cancer Res Clin Oncol. 2019;145(3):615–623.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Chobrutskiy BI, Zaman S, Tong WL, et al. Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade. J Neurooncol. 2018;140(3):697–704.
   PubMed Web of Science ®Google Scholar
• Xie C, Yeo ZX, Wong M, et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. Proc Natl Acad Sci U S A. 2017;114(30):8059–8064.
   PubMed Web of Science ®Google Scholar
• Callahan BM, Tong WL, Blanck G. T cell receptor-β J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates. Immunol Res. 2018;66(2):219–223.
   PubMed Web of Science ®Google Scholar
• Callahan BM, Patel JS, Fawcett TJ, et al. Cytoskeleton and ECM tumor mutant peptides: increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir. Int J Cancer. 2018;142(5):988–998.
   PubMed Web of Science ®Google Scholar
• Callahan BM, Yavorski JM, Tu YN, et al. T-cell receptor-β V and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patterns. Cancer Immunol Immunother. 2018;67(6):885–892.
   PubMed Web of Science ®Google Scholar
• Tong WL, Callahan BM, Tu YN, et al. Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Res Treat. 2019;173(1):167–177.
   PubMed Web of Science ®Google Scholar
• Heike M, Duchmann R, May E, et al. Dominant TCRB-V–J chain usage and clonal expansion of sarcoma-reactive CD4+ HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma antigens. Int J Cancer. 1997;72(3):403–407.
   PubMed Web of Science ®Google Scholar
• Faham M, Carlton V, Moorhead M, et al. Discovery of T cell receptor β motifs specific to HLA-B27-positive ankylosing spondylitis by deep repertoire sequence analysis. Arthritis Rheumatol. 2017;69(4):774–784.
   PubMed Web of Science ®Google Scholar
• Zeng G, Huang Y, Huang Y, et al. Antigen-specificity of T cell infiltrates in biopsies with T cell-mediated rejection and BK polyomavirus viremia: analysis by next generation sequencing. Am J Transplant. 2016;16(11):3131–3138.
   PubMed Web of Science ®Google Scholar
• Di Sante G, Tolusso B, Fedele AL, et al. Collagen specific T-cell repertoire and HLA-DR alleles: biomarkers of active refractory rheumatoid arthritis. EBioMedicine. 2015;2(12):2037–2045.
   PubMed Web of Science ®Google Scholar
• Klarenbeek PL, Doorenspleet ME, Esveldt RE, et al. Somatic variation of T-cell receptor genes strongly associate with HLA class restriction. PLOS One. 2015;10(10):e0140815.
   PubMed Web of Science ®Google Scholar
• Britanova OV, Putintseva EV, Shugay M, et al. Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. J Immunol. 2014;192(6):2689–2698.
   PubMed Web of Science ®Google Scholar